Fayaz A. Malik | |
|---|---|
| Born | India |
| Nationality | Indian |
| Known for | Studies involve understanding the regulation of Cancer Stem Cells during tumor metastasis in Breast Cancer and discovery of new targets and target based therapeutic agents addressing drug resistant cancers. |
| Awards |
|
| Scientific career | |
| Fields |
|
| Institutions | |
Dr. Fayaz Ahmad Malik is an Indian pharmacologist, cancer biologist and a scientist at the Indian Institute of Integrative Medicine of the Council of Scientific and Industrial Research. He is known for his studies on investigating the regulatory mechanisms of Cancer Stem Cells during tumor metastasis. His studies also involve the identification of signaling networks conferring resistance to current anti-cancer therapies. His discovery of new anticancer agents holds a number of patents for the processes he has developed. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to Biosciences, in 2014. [1]
The Department of Science and Technology (DST) of the Government of India awarded him the Swaranajayanti Fellowship, one of the prestigious Fellowship awards, for his advanced research in cancer biology, in 2013-14. Council of Scientific and Industrial Research felicitated him with CSIR-Young Scientist Award (CSIR-YSA) in 2009. In 2010 Government of Jammu and Kashmir also awarded him with Young Scientist Award in Biological Sciences.
Fayaz Malik, after securing a master's degree in biotechnology and a PhD,. [2] He started his career by joining the Indian Institute of Integrative Medicine of the Council of Scientific and Industrial Research where he is a senior scientist of the Cancer Research and Drug Discovery group. [3] His major research focus remains to understand the critical regulatory biological mechanisms predisposed to the failure of current therapies, acquired resistance, and the onset of metastasis by exploring cellular catabolic machinery and regulatory networks of Cancer Stem Cells in subtypes of breast cancer. [4] He has also developed many processes for which he holds the patents. [5] [6] [7] His studies have been documented by way of a number of articles [8] [note 1] and Google Scholar, an online repository of scientific articles has listed 70 of them. [9] Besides, he has contributed chapters to books published by others. [10] He has also participated in various seminars and conferences to give invited speeches. [11] [12]
Malik received the Young Scientist of Year Award from the Council of Scientific and Industrial Research in 2009 and Young Scientist Awards from Jammu and Kashmir Government in 2010 [13] The Department of Biotechnology (DBT) of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards in 2014. [1] Malik has been bestowed with several other international awards and fellowships in various conferences and workshops.
Autophagy is the natural, conserved degradation of the cell that removes unnecessary or dysfunctional components through a lysosome-dependent regulated mechanism. It allows the orderly degradation and recycling of cellular components. Although initially characterized as a primordial degradation pathway induced to protect against starvation, it has become increasingly clear that autophagy also plays a major role in the homeostasis of non-starved cells. Defects in autophagy have been linked to various human diseases, including neurodegeneration and cancer, and interest in modulating autophagy as a potential treatment for these diseases has grown rapidly.
Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.
Chelerythrine is a benzophenanthridine alkaloid present in the plant Chelidonium majus. It is a potent, selective, and cell-permeable protein kinase C inhibitor in vitro. And an efficacious antagonist of G-protein-coupled CB1 receptors. This molecule also exhibits anticancer qualities and it has served as a base for many potential novel drugs against cancer. Structurally, this molecule has two distinct conformations, one being a positively charged iminium form, and the other being an uncharged form, a pseudo-base.
Genistein (C15H10O5) is a naturally occurring compound that structurally belongs to a class of compounds known as isoflavones. It is described as an angiogenesis inhibitor and a phytoestrogen.
Ormeloxifene, also known as centchroman, is one of the selective estrogen receptor modulators, or SERMs, a class of medication which acts on the estrogen receptor. It is best known as a nonsteroidal oral contraceptive which is taken once per week. In India, ormeloxifene has been available as birth control since the early 1990s, and it was marketed there under the trade name Saheli, currently available free-of-cost for the women in India as Chhaya (Centchroman).
Gopal Chandra Kundu is an Indian cell and cancer biologist and a Senior Scientist (Scientist-G) at National Centre for Cell Science. He is known for his contributions towards the understanding the mechanism of cancer progression in breast, melanoma and other cancers and development of novel therapeutic targets and target-based therapy in cancers.
Paul Talalay was the John Jacob Abel Distinguished Service Professor of Pharmacology and director of the Laboratory for Molecular Sciences at the Johns Hopkins School of Medicine in Baltimore. He was the founder of the Brassica Chemoprotection Laboratory for the study of edible plants that induce protective enzyme activity in the body and may help prevent the development of cancer.
Jane Visvader is a scientist specialising in breast cancer research who works for the Walter and Eliza Hall Institute in Melbourne, Australia. She is the joint head of the Breast Cancer Laboratory with Geoff Lindeman.
Molly S. Shoichet, is a Canadian science professor, specializing in chemistry, biomaterials and biomedical engineering. She was Ontario's first Chief Scientist. Shoichet is a biomedical engineer known for her work in tissue engineering, and is the only person to be a fellow of the three National Academies in Canada.
Amit Dutt is an Indian scientist, geneticist and the principal investigator at Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of Tata Memorial Centre. Known for his studies on Fibroblast growth factor receptor, Dutt is a Wellcome Trust / DBT India Alliance Intermediate Fellow. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, for his contributions to medical sciences in 2017.
Weiping Zou is the Charles B. de Nancrede Professor of Pathology, Immunology, Biology, and Surgery at the University of Michigan. He is a scientist noted for his work regarding understanding the nature of human tumor immune responses and developing mechanism-informed combination therapies for cancer. He has developed an international reputation in human tumor immunosuppressive mechanisms in the tumor microenvironment.
Sunil Kumar Manna is an Indian immunologist and the head of the immunology lab of the Centre for DNA Fingerprinting and Diagnostics. He is known for his studies on cell signaling and apoptosis. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2009.
Sujata Sharma is an Indian structural biologist, biophysicist, writer and a professor at the Department of Biophysics of the All India Institute of Medical Sciences, Delhi. She is known for her studies in the fields of protein structure, drug design and drug resistance of bacteria. Her studies have been documented by way of a number of articles and ResearchGate, an online repository of scientific articles has listed 167 of them. She is also the author of the books, "Warriors in White", an autobiographical account of some COVID-19 Warriors at All India Institute of Medical Sciences, Delhi and other leading hospitals of India, including Prof Randeep Guleria, using a combination of modern medicine, astronomy and Vedic astrology, "The Secret of the Red Crystals", an autobiographical account of her days in AIIMS Delhi. and "A Dragonfly's purpose", which is an autobiographical account of her recovery from an autoimmune disease, Guillain Barre Syndrome. The Department of Biotechnology of the Government of India awarded her the National Bioscience Award for Career Development, one of the highest Indian science awards, for her contributions to biosciences, in 2011. She is also a recipient of the Woman Scientist Award of the Biotech Research Society of India and the National Young Woman Bioscientist Award of the Department of Biotechnology which she received in 2006 and 2007 respectively. In 2020, she was awarded the Kalpana Chawla Excellence award, for her contributions in science. This award is instituted in the memory of the first Indian woman astronaut, Kalpana Chawla to go on space missions.
Aditya Bhushan Pant is an Indian toxicologist, neurobiologist and a scientist at the Indian Institute of Toxicology Research. He is known for his studies in the fields of developmental toxicology, in vitro experiments as well as pesticides and is a member of the Neurobiology Task force of the Department of Biotechnology. His studies have been documented by way of a number of articles and ResearchGate, an online repository of scientific articles has listed 121 of them. Besides, he has contributed chapters to books published by others and is an associate editor of the Annals of Neurosciences journal of the Indian Academy of Neurosciences. He is a recipient for the Shakuntala Amir Chand Prize of the Indian Council of Medical Research in 2007. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2012.
Pawan Gupta is an Indian biotechnologist, immunobiologist, cell biologist and a Senior principal scientist at the Institute of Microbial Technology of the Council of Scientific and Industrial Research. He is known for his studies on Nuclear Receptors in Chronic Inflammatory Disorders and host-pathogen interaction of Mycobacterium tuberculosis. His studies have been documented by way of a number of articles and ResearchGate, an online repository of scientific articles has listed 66 of them. The Department of Biotechnology of the Government of India awarded him the DBT IYBA Award in 2009 and National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2015.
Ashwani Kumar is an Indian microbiologist and the Senior Principal Scientist at the Institute of Microbial Technology (ImTech). He is known for his studies on Mycobacterium tuberculosis, the causative agent of tuberculosis. His laboratory focuses on understanding the reasons for drug tolerance observed in humans. His laboratory hypothesizes that tuberculosis is a biofilm infection, so its treatment needs the administration of multiple drugs for at least six months. The Department of Science and Technology has awarded him Swarnajayanti Fellowship for 2016–2017. Department of Biotechnology has awarded him the National Bioscience Prize (2017-18). He was also selected for DBT/Wellcome Trust India Alliance Senior Fellowship. He was elected as a Fellow of the National Academy of Sciences, India, in 2022. For his contributions in tuberculosis pathogenesis, he was awarded with Shanti Swarup Bhatnagar Prize for Science and Technology 2022. He is considered as one of India's Leading Scientist in the field of Tuberculosis and his lab is doing some of the best research in India.
Thea D. Tlsty is an American pathologist and professor of pathology at the University of California, San Francisco (UCSF). She is known for her research in cancer biology and her involvement in the discovery of cells that may be at the origin of metaplastic cancer, an invasive form of breast cancer.
The University of Michigan Rogel Cancer Center is a cancer research and treatment institution based in Ann Arbor, Michigan, United States. The Rogel Cancer Center is affiliated with the University of Michigan and Michigan Medicine.
Roberta Anne Gottlieb is an American oncologist, academic, and researcher. She is a Professor, and Vice-Chair of Translational Medicine in the Department of Biomedical Sciences at Cedars-Sinai Medical Center, and a Professor of Medicine at the University of California, Los Angeles.
Recurrent cancer is a form of cancer that has returned or recurred when a fraction of primary tumor cells evade the effects of treatment and survive in small spaces that are undetectable by diagnostic tests. The initial tumor may become the site of cancer’s return or it may spread to another part of the body. These surviving cells accumulate various genetic changes over time, eventually producing a new tumor cell. It can take up to weeks, months, or even years for cancer to return. Following surgery and/or chemotherapy or radiotherapy, certain tumor cells may persist and develop resistance to treatment and eventually develop into new tumors. Age, sex, cancer type, treatment duration, stage of advancement, and grade of original tumor are some of the factors that determine the rate of cancer recurrence. If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original cancer. In general, the severity of cancer increases with a shorter duration of time between initial treatment and its return.
{{cite book}}: CS1 maint: multiple names: authors list (link)| Authority control databases: Academics |
|---|
